Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10515051 | 0.87 | MAPT (0.55) | SMN1; SMN2ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL10488583 | 0.87 | LMNA (0.53) | SMN1; SMN2ALDH1A1LMNAMAPK1MEN1 | |
| SCHEMBL18282552 | 0.82 | PRMT1 (0.53) | SMN1; SMN2PRMT1ALDH1A1LMNAMAPK1 | |
| SCHEMBL18282493 | 0.81 | PRMT1 (0.53) | SMN1; SMN2PRMT1ALDH1A1LMNAMAPK1 | |
| SCHEMBL10565099 | 0.78 | PDE4D (0.56) | SMN1; SMN2ALDH1A1MAPK1KMT2AMAPT | |
| SCHEMBL2456713 | 0.77 | PRMT1 (0.53) | PRMT1ALDH1A1LMNAMAPK1KDM4E | |
| SCHEMBL20438319 | 0.77 | MEN1 (0.55) | ALDH1A1LMNAMAPK1MEN1KMT2A | |
| SCHEMBL10518574 | 0.77 | PDE4D (0.55) | SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL9836988 | 0.76 | PRMT1 (0.54) | SMN1; SMN2PRMT1ALDH1A1LMNAMAPK1 | |
| SCHEMBL3318522 | 0.75 | PRMT1 (0.68) | SMN1; SMN2PRMT1ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4871737-A | 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-03 | — | — | US | claimed |
| EP-0315433-A2 | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-10 | — | — | EP | claimed |
| US-10774074-B2 | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists | ORION CORPORATION (FI) | 2020-09-15 | — | — | US | disclosed |
| US-20190292170-A9 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2019-09-26 | — | — | US | disclosed |
| US-20180215739-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2018-08-02 | — | — | US | disclosed |
| US-4871737-A | 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0315433-A2 | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4826866-A | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215739-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | OPRM1, HTR2C, ADRA2C | SMN1; SMN2 93/4885PRMT1 2544/4885ALDH1A1 972/4885 |
| US-10774074-B2 | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists | OPRM1, HTR2C, ADRA2C | SMN1; SMN2 93/4885PRMT1 2544/4885ALDH1A1 972/4885 |
| US-20190292170-A9 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | OPRM1, HTR2C, ADRA2C | SMN1; SMN2 93/4885PRMT1 2544/4885ALDH1A1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.